Chemomab Therapeutics (CMMB) Competitors $1.30 -0.21 (-13.91%) Closing price 04:00 PM EasternExtended Trading$1.31 +0.01 (+0.77%) As of 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CMMB vs. ADVM, SKYE, ALTS, ANL, CRBP, ANRO, RANI, PLRX, IFRX, and JSPRShould you be buying Chemomab Therapeutics stock or one of its competitors? The main competitors of Chemomab Therapeutics include Adverum Biotechnologies (ADVM), Skye Bioscience (SKYE), Janone (ALTS), Adlai Nortye (ANL), Corbus Pharmaceuticals (CRBP), Alto Neuroscience (ANRO), Rani Therapeutics (RANI), Pliant Therapeutics (PLRX), InflaRx (IFRX), and Jasper Therapeutics (JSPR). These companies are all part of the "pharmaceutical products" industry. Chemomab Therapeutics vs. Adverum Biotechnologies Skye Bioscience Janone Adlai Nortye Corbus Pharmaceuticals Alto Neuroscience Rani Therapeutics Pliant Therapeutics InflaRx Jasper Therapeutics Chemomab Therapeutics (NASDAQ:CMMB) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, community ranking, risk and valuation. Does the MarketBeat Community believe in CMMB or ADVM? Adverum Biotechnologies received 350 more outperform votes than Chemomab Therapeutics when rated by MarketBeat users. However, 65.52% of users gave Chemomab Therapeutics an outperform vote while only 60.20% of users gave Adverum Biotechnologies an outperform vote. CompanyUnderperformOutperformChemomab TherapeuticsOutperform Votes1965.52% Underperform Votes1034.48% Adverum BiotechnologiesOutperform Votes36960.20% Underperform Votes24439.80% Do analysts recommend CMMB or ADVM? Chemomab Therapeutics currently has a consensus price target of $9.00, indicating a potential upside of 592.31%. Adverum Biotechnologies has a consensus price target of $27.83, indicating a potential upside of 554.90%. Given Chemomab Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Chemomab Therapeutics is more favorable than Adverum Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chemomab Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Adverum Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Which has more volatility & risk, CMMB or ADVM? Chemomab Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Which has better valuation & earnings, CMMB or ADVM? Chemomab Therapeutics has higher earnings, but lower revenue than Adverum Biotechnologies. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChemomab TherapeuticsN/AN/A-$24.22M-$1.00-1.30Adverum Biotechnologies$1M88.41-$117.17M-$5.99-0.71 Is CMMB or ADVM more profitable? Adverum Biotechnologies' return on equity of -65.14% beat Chemomab Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Chemomab TherapeuticsN/A -101.70% -76.18% Adverum Biotechnologies N/A -65.14%-40.52% Does the media favor CMMB or ADVM? In the previous week, Adverum Biotechnologies had 2 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 8 mentions for Adverum Biotechnologies and 6 mentions for Chemomab Therapeutics. Chemomab Therapeutics' average media sentiment score of 0.96 beat Adverum Biotechnologies' score of 0.48 indicating that Chemomab Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Chemomab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adverum Biotechnologies 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of CMMB or ADVM? 46.0% of Chemomab Therapeutics shares are held by institutional investors. Comparatively, 48.2% of Adverum Biotechnologies shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by company insiders. Comparatively, 4.2% of Adverum Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryAdverum Biotechnologies beats Chemomab Therapeutics on 9 of the 16 factors compared between the two stocks. Get Chemomab Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMMB vs. The Competition Export to ExcelMetricChemomab TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.67M$7.21B$5.80B$8.35BDividend YieldN/A2.80%4.76%3.97%P/E Ratio-1.306.2024.9219.12Price / SalesN/A188.49374.24113.03Price / CashN/A65.6738.0534.62Price / Book0.846.417.314.26Net Income-$24.22M$139.72M$3.19B$246.62M7 Day Performance-16.13%-3.40%-3.20%-3.75%1 Month Performance-37.20%-9.16%-7.06%-6.89%1 Year Performance98.32%-12.87%12.06%3.39% Chemomab Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMMBChemomab Therapeutics3.6511 of 5 stars$1.30-13.9%$9.00+592.3%+128.8%$18.67MN/A-1.3020Upcoming EarningsNews CoverageGap DownADVMAdverum Biotechnologies3.985 of 5 stars$4.16-11.7%$27.83+569.1%-78.9%$86.54M$1M-0.69190News CoverageSKYESkye Bioscience1.0095 of 5 stars$2.51-8.2%$18.67+645.2%-85.0%$86.46MN/A0.0011Gap UpALTSJanoneN/A$5.53-8.6%N/AN/A$85.12M$7.11M0.00170Short Interest ↑News CoverageGap DownANLAdlai Nortye2.7375 of 5 stars$2.30+1.8%$9.00+291.3%-70.9%$84.87M$5M0.00127Short Interest ↓Positive NewsGap DownHigh Trading VolumeCRBPCorbus Pharmaceuticals3.8068 of 5 stars$6.96-7.8%$61.38+781.8%-80.1%$84.77MN/A-1.4840Upcoming EarningsGap DownANROAlto Neuroscience1.4756 of 5 stars$3.14+12.1%$16.75+433.4%-78.9%$84.69MN/A0.00N/AGap UpHigh Trading VolumeRANIRani Therapeutics3.1379 of 5 stars$1.47-3.9%$12.33+739.0%-60.2%$84.22MN/A-1.39110Short Interest ↑PLRXPliant Therapeutics4.6823 of 5 stars$1.38-59.9%$13.88+905.4%-91.7%$83.98M$1.58M-0.4190Earnings ReportAnalyst DowngradeShort Interest ↓News CoverageGap UpHigh Trading VolumeIFRXInflaRx3.3048 of 5 stars$1.25-10.1%$8.00+540.0%-28.6%$83.92M$168,498.00-1.1660High Trading VolumeJSPRJasper Therapeutics3.5458 of 5 stars$5.58-5.9%$64.44+1,054.9%-74.7%$83.71MN/A-1.1820Earnings ReportAnalyst Revision Related Companies and Tools Related Companies ADVM Competitors SKYE Competitors ALTS Competitors ANL Competitors CRBP Competitors ANRO Competitors RANI Competitors PLRX Competitors IFRX Competitors JSPR Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CMMB) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored77 Hedge Funds Are Betting On This Off-Radar MineralWith surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fa...The Tomorrow Investor | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | SponsoredWhy 2026 will be a disaster for many AmericansWall Street Legend: Why stocks are very likely to crash in Trump's 2nd Year Legendary investor Marc Chaikin...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemomab Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
